# Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

> **NCT03563937** · — · COMPLETED · sponsor: **Bayer** · enrollment: 64920 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Phenprocoumon
- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Edoxaban

## Key facts

- **NCT ID:** NCT03563937
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2019-12-10
- **Final completion:** 2019-12-10
- **Target enrollment:** 64920 (ACTUAL)
- **Last updated:** 2020-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563937, "Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03563937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*